title: Prolonged remission in a patient with relapsed follicular lymphoma after a single course of rituximab.
abstract: BACKGROUND
  Rituximab monotherapy can achieve remissions of up to 80% in follicular lymphoma. As the antibody has only been on the market since 1997, long-term observations are still rare.
  
  
  METHODS
  We report about a patient with follicular lymphoma who received a single treatment of 4 x 375 mg/m(2) of the monoclonal antibody rituximab without chemotherapy and has been in complete remission (CR) for 8 years.
  
  
  CONCLUSIONS
  This remarkable response duration highlights the efficacy of rituximab monotherapy. A number of recently published studies have indicated that CR of more than 4 years after rituximab monotherapy may be a regularly occurring event.
  
  
  CONCLUSIONS
  These patients are likely to represent a yet poorly characterized patient group that profits considerably from rituximab monotherapy.
authors.affiliation: Department of Internal Medicine I, University of Cologne, Germany. jensen@uni-koeln.de
authors.forename: Markus
authors.initials: M
authors.lastname: Jensen
authors.forename: Thomas
authors.initials: T
authors.lastname: Elter
authors.forename: Andreas
authors.initials: A
authors.lastname: Engert
authors.forename: Marcel
authors.initials: M
authors.lastname: Reiser
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D000069283:Rituximab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab